The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.
Zhang Y, Sieuwerts AM, McGreevy M, Casey G, Cufer T, Paradiso A, Harbeck N, Span PN, Hicks DG, Crowe J, Tubbs RR, Budd GT, Lyons J, Sweep FC, Schmitt M, Schittulli F, Golouh R, Talantov D, Wang Y, Foekens JA.
Zhang Y, et al. Among authors: paradiso a.
Breast Cancer Res Treat. 2009 Jul;116(2):303-9. doi: 10.1007/s10549-008-0183-2. Epub 2008 Sep 23.
Breast Cancer Res Treat. 2009.
PMID: 18821012
Clinical Trial.